TW200410682A - Treatment of anorexia nervosa (an) and bulimia - Google Patents
Treatment of anorexia nervosa (an) and bulimia Download PDFInfo
- Publication number
- TW200410682A TW200410682A TW092125483A TW92125483A TW200410682A TW 200410682 A TW200410682 A TW 200410682A TW 092125483 A TW092125483 A TW 092125483A TW 92125483 A TW92125483 A TW 92125483A TW 200410682 A TW200410682 A TW 200410682A
- Authority
- TW
- Taiwan
- Prior art keywords
- epa
- pharmaceutical composition
- acid
- treatment
- patent application
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 208000000103 Anorexia Nervosa Diseases 0.000 title claims abstract description 29
- 208000032841 Bulimia Diseases 0.000 title claims abstract description 10
- 206010006550 Bulimia nervosa Diseases 0.000 title claims abstract description 10
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 37
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 36
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 36
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 208000035850 clinical syndrome Diseases 0.000 claims abstract description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 5
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims 1
- 241001553178 Arachis glabrata Species 0.000 claims 1
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 1
- 235000018262 Arachis monticola Nutrition 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 17
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 17
- 235000013305 food Nutrition 0.000 description 10
- 230000003340 mental effect Effects 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 235000005686 eating Nutrition 0.000 description 7
- 230000004630 mental health Effects 0.000 description 7
- 230000036651 mood Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000022531 anorexia Diseases 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001671 psychotherapy Methods 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 3
- 230000037237 body shape Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 238000009231 family therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000036301 sexual development Effects 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101150031621 CGAS gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010016280 Fear of weight gain Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010036155 Poor peripheral circulation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229940066279 eicosapentaenoate Drugs 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000002369 psychoeducation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- -1 sodium H Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200410682A true TW200410682A (en) | 2004-07-01 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092125483A TW200410682A (en) | 2002-09-16 | 2003-09-16 | Treatment of anorexia nervosa (an) and bulimia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (https=) |
| EP (1) | EP1556028A1 (https=) |
| JP (1) | JP2006503031A (https=) |
| KR (1) | KR20050042823A (https=) |
| CN (1) | CN1694694A (https=) |
| AU (1) | AU2003269138A1 (https=) |
| BR (1) | BR0317857A (https=) |
| CA (1) | CA2499142A1 (https=) |
| GB (1) | GB0221480D0 (https=) |
| HR (1) | HRP20050245A2 (https=) |
| IS (1) | IS7744A (https=) |
| MX (1) | MXPA05002943A (https=) |
| NO (1) | NO20051847L (https=) |
| NZ (1) | NZ538793A (https=) |
| PL (1) | PL375726A1 (https=) |
| RS (1) | RS20050226A (https=) |
| RU (1) | RU2330653C2 (https=) |
| TW (1) | TW200410682A (https=) |
| WO (1) | WO2004024136A1 (https=) |
| ZA (1) | ZA200502161B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| EP2098229A4 (en) | 2006-12-28 | 2010-03-10 | Suntory Holdings Ltd | NERVE REGENERATION MEDIUM |
| DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| CA2677670C (en) | 2007-03-20 | 2010-08-03 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP3318255B1 (en) * | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| EP2673371A1 (en) * | 2011-02-11 | 2013-12-18 | E.I. Du Pont De Nemours And Company | An eicosapentaenoic acid concentrate |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
| WO2019153073A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| WO2019204218A1 (en) * | 2018-04-16 | 2019-10-24 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| EP3787614B1 (en) | 2018-05-03 | 2024-07-31 | SCF Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12144786B2 (en) | 2020-03-27 | 2024-11-19 | Homeostasis Therapeutics LLC | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
-
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200502161B (en) | 2005-09-15 |
| RS20050226A (sr) | 2007-09-21 |
| NO20051847L (no) | 2005-04-15 |
| PL375726A1 (en) | 2005-12-12 |
| EP1556028A1 (en) | 2005-07-27 |
| CA2499142A1 (en) | 2004-03-25 |
| HRP20050245A2 (en) | 2005-10-31 |
| CN1694694A (zh) | 2005-11-09 |
| BR0317857A (pt) | 2005-12-06 |
| GB0221480D0 (en) | 2002-10-23 |
| JP2006503031A (ja) | 2006-01-26 |
| AU2003269138A1 (en) | 2004-04-30 |
| RU2330653C2 (ru) | 2008-08-10 |
| US20060135608A1 (en) | 2006-06-22 |
| WO2004024136A1 (en) | 2004-03-25 |
| MXPA05002943A (es) | 2005-06-03 |
| IS7744A (is) | 2005-03-15 |
| KR20050042823A (ko) | 2005-05-10 |
| NZ538793A (en) | 2007-05-31 |
| RU2005107416A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200410682A (en) | Treatment of anorexia nervosa (an) and bulimia | |
| JPH0625006A (ja) | 免疫障害、炎症および慢性感染症を治療するための方法および組成物 | |
| JP2004521919A (ja) | 抗ストレス機能、抗疲労機能、月経前期症候群及び月経痛緩和機能及び脳神経栄養因子としての機能を有する酵母由来機能性ペプチド及びその製造方法 | |
| JP2008519847A (ja) | 運動障害の治療方法 | |
| JP2003510353A (ja) | 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用 | |
| Salvesen et al. | Idiopathic hypoparathyroidism | |
| JP2011241209A (ja) | ガングリオシド又はその誘導体を有効成分とするｂｄｎｆ産生促進剤並びにそれを含有する医薬品、飲食品及び飼料 | |
| Dahlstrom et al. | Nutritional status in children receiving home parenteral nutrition | |
| CN116098918B (zh) | 一种胞磷胆碱药物组合物及其用途 | |
| CN115025105B (zh) | 唾液酸在减轻体重和抑制体重增加中的应用 | |
| DK2849724T3 (en) | MEDIUM TO PROMOTE FOOD INTAKE AND FOOD RETENTION | |
| JP6368368B2 (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| JPWO2002060457A1 (ja) | 抗ストレス剤 | |
| Bhalkar et al. | Ayurveda treatment modalities for improving the quality of life in Sickle Cell Anaemia A case study | |
| Wang et al. | Swallowing function and neuropsychological status in patients with dysphagia after stroke: literature review and nursing intervention | |
| NEFF | The treatment of colic in infants | |
| LIST | Standard Treatment guidelines | |
| Calcaterra et al. | Breastfeeding and maternal exercise: A synergistic approach to improve cardiometabolic health | |
| CN121003686A (zh) | 乳清蛋白在制备治疗抽动障碍的药物中的用途 | |
| US6555531B1 (en) | Weight promoting composition, method, and product | |
| CN121648265A (zh) | 司美格鲁肽与丁酸钠联用在制备用于减重的药物中的应用 | |
| WO2025218622A1 (zh) | 用于改善生殖健康的方法和组合物 | |
| Jain | A Randomized Placebo Controlled Clinical Trial to Evaluate the Efficacy of Vidarikandadi Churna in the Management of Balashosha WSR to Underweight Children | |
| Sainani et al. | Manual of Clinical & Practical Medicine | |
| SENSIBILITY | were defatted by prolonged extraction with benzoyl chloride. There was no preliminary acid treatment |